Rxsight Inc RXST.OQ RXST.O is expected to show a fall in quarterly revenue when it reports results on November 5 for the period ending September 30 2025
The Aliso Viejo California-based company is expected to report a 28.4% decrease in revenue to $25.278 million from $35.31 million a year ago, according to the mean estimate from 9 analysts, based on LSEG data.
LSEG's mean analyst estimate for Rxsight Inc is for a loss of 38 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 8 "hold" and 2 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Rxsight Inc is $9.00, about 2.3% above its last closing price of $8.79
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.26 | -0.24 | -0.29 | Missed | -19 |
Mar. 31 2025 | -0.22 | -0.22 | -0.20 | Beat | 7.4 |
Dec. 31 2024 | -0.16 | -0.17 | -0.15 | Beat | 9.3 |
Sep. 30 2024 | -0.24 | -0.25 | -0.16 | Beat | 35 |
Jun. 30 2024 | -0.22 | -0.22 | -0.16 | Beat | 28.4 |
Mar. 31 2024 | -0.26 | -0.27 | -0.25 | Beat | 6.1 |
Dec. 31 2023 | -0.36 | -0.36 | -0.26 | Beat | 28.2 |
Sep. 30 2023 | -0.43 | -0.43 | -0.31 | Beat | 28.5 |
This summary was machine generated November 3 at 22:30 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments